New oral solid dosage form for furosemide oral administration

详细信息	查看全文 | 推荐本文 |

• 作者：Luana Perioli^a ; ^{luanaper@unipg.it} ; Giuseppina D’ ; Alba^b ; Cinzia Pagano^a
• 关键词：Super disintegrants ; Hydrotalcite ; Tablets ; Furosemide ; Dissolution
• 刊名：European Journal of Pharmaceutics and Biopharmaceutics
• 出版年：2012
• 期刊代码：16_09396411
• 类别：pha
• 出版时间：April, 2012
• 卷：80
• 期：3
• 页码：621-629
• 文件大小：736 K

摘要

Furosemide (FURO) is a drug labeled in class IV of the Biopharmaceutics Classification System (BCS) as it is both poor soluble and poor permeable.

The aim of this work was to improve FURO biopharmaceutical properties by its formulation in a new solid oral dosage form. It consists in the realization of the composite MgAl-HTlc-FURO, obtained by FURO intercalation into the inorganic matrix hydrotalcite (MgAl-HTlc), and its successive formulation in tablets intended to be swallowed whole and to disintegrate rapidly in the stomach. These formulations were prepared by direct compression of a simple powder mixture constituted by MgAl-HTlc-FURO, a super disintegrant (Explotab庐, Polyplasdone庐XL, Polyplasdone庐XL-10, Polyplasdone庐INF 10 or L-HPC庐LH-21) and a filler.

The prepared formulations were submitted to disintegration time tests, and only those displaying the lowest disintegration time in gastric medium were submitted to in vitro release studies. Drug dissolution profiles from MgAl-HTlc-FURO tablets were compared with those containing crystalline FURO alone or physically mixed to MgAl-HTlc instead of MgAl-HTlc-FURO. The results revealed that tablets containing MgAl-HTlc-FURO give the best dissolution profile and that L-HPC庐LH-21 is able to promote the highest drug release in gastric medium, resulting in the most suitable super disintegrant in comparison with the other tested.